Theramex Announces Licensing Agreement with ObsEva for the Commercialisation of Linzagolix for the Treatment of Uterine Fibroids
Theramex, a leading global pharmaceutical company specialising in women's health, has entered into a licensing agreement with ObsEva SA, a biopharmaceutical company developing and commercializing novel